Cardiovascular monitoring and therapy for HIV-infected patients

Annals of the New York Academy of Sciences

Volumn 946, Issue , 2001, Pages 236-273

  Lipshultz, Steven E ^a,b   Fisher, Stacy D ^a,b   Lai, Wyman W ^a,c,d   Miller, Tracie L ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c MOUNT SINAI HOSPITAL   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Atherosclerosis; Cardiovascular; Congestive heart failure; HIV

Indexed keywords

AMYLOID A PROTEIN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ETANERCEPT; FIBRINOGEN; FIBRINOLYTIC FACTOR; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERSTITIAL COLLAGENASE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTOXIFYLLINE; PHOSPHOLIPASE A2; PROCOAGULANT; STROMELYSIN; TROPONIN T; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIET; ECHOCARDIOGRAPHY; ELECTRON BEAM TOMOGRAPHY; EXERCISE; EXERCISE TEST; GENETIC PREDISPOSITION; HEART CATHETERIZATION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEART SCINTISCANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; ISCHEMIC HEART DISEASE; NEOPLASM; PATIENT MONITORING; PERICARDIOCENTESIS; SMOKING CESSATION;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0035202797     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03916.x     Document Type: Conference Paper

References (286)

1. Cardiac complications in children with human immunodeficiency virus infection
2. Cardiac involvement in the acquired immunodeficiency syndrome: A multicenter clinical-pathological study
3. Cardiac complications in acquired immunodeficiency syndrome (AIDS): A review
4. Cardiac manifestations of acquired immunodeficiency syndrome
5. Cardiac morbidity and related mortality in children with HIV infection
6. Early impairment of systolic and diastolic function in asymptomatic HIV-positive patients: A multicenter echocardiographic and echo-doppler study
7. Pericardial effusion in AIDS. Incidence and survival
8. Pericardial involvement in human immunodeficiency virus infection
9. A review of endocarditis in acquired immunodeficiency syndrome and human immunodeficiency virus infection
10. Infective endocarditis in intravenous drug users: A comparison of human immunodeficiency virus type 1-negative and -positive patients
11. Cardiac cancers in HIV-infected patients
12. Pulmonary hypertension in patients infected with HIV
13. Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome
14. Primary pulmonary hypertension and HIV infection
15. Primary pulmonary hypertension associated with human immunodeficiency viral infection
16. 2 HIV multicenter study
17. 2 HIV multicenter study
18. Immunoglobulins and left ventricular structure and function in pediatric HIV infection
19. Autonomic function and human immunodeficiency virus infection
20. Torsades des pointes during administration of pentamidine isethionate
21. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients
22. Prediction of coronary events with electron beam computed tomography
23. Electron beam tomography and national cholesterol education program guidelines in asymptomatic women
24. Coronary calcium as a risk factor: Role in global risk assessment
25. Noninvasive tests of vascular function and structure: Why and how to perform them
26. Which tools are in your cardiac workshop? Carotid ultrasound, endothelial function, and magnetic resonance imaging
27. 2 HIV multicenter study
28. Coronary angiography and intravascular ultrasound
29. Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms
30. Cardiovascular monitoring of HIV-infected patients
31. Cardiac therapeutics in HIV-infected patients
32. Cardiac disease
33. The detection of viral genomes by polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease
34. Malnutrition and cardiac abnormalities in the HIV-infected patient
35. Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus
36. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury
37. New developments in the biochemical assessment of myocardial injury in children: Troponin T and I as highly sensitive and specific markers of myocardial injury
38. The utility of brain natriuretic peptides in patients with heart failure and coronary artery disease
39. The natriuretic peptides in heart failure: Diagnostic and therapeutic potentials
40. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction
41. Laboratory surrogates for anti-atherosclerotic drug development
42. High-sensitivity C-reactive protein: A novel inflammatory marker for predicting the risk of coronary artery disease
43. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
44. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
45. Clinical efficacy of an automated high-sensitivity C-reactive protein assay
46. Production of C-reactive protein and risk of coronary events in stable and unstable angina
47. Lipoprotein associated phospholipase A2 as an independent predictor of coronary heart disease
48. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions
49. Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins
50. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: Use of a novel inhibitor
51. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the adult AIDS clinical trial group cardiovascular disease focus group
52. Use of surrogate endpoints: A practical necessity in lipid-altering and antiatherosclerosis drug development
53. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy
54. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec cardiovascular study
55. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting
56. 2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events
57. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure
58. Preprescription genotyping. Not yet ready for prime time, but getting there
59. Prediction of coronary heart disease using risk factor categories
60. Hypertension in the HIV-infected patient
61. How many medicines do patients with heart failure need?
62. Results of targeted anti-TNF therapy with Etanercept (ENBREL) in patients with advanced heart failure
63. Use of OKT3 for acute myocarditis in infants and children
64. Effects of vesnarinone on morbidity and mortality in patients with heart failure
65. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
66. Prevention of autoimmune myocarditis through the induction of antigen-specific peripheral immune tolerance
67. Drugs for non-HIV viral infections
68. Heart failure
69. Heart failure disease management: 1 critical review
70. Exercise and its role in the prevention and rehabilitation of cardiovascular disease
71. Management of heart failure. II. Counseling, education and lifestyle modification
72. Experience from controlled trials of physical training in chronic heart failure. Protocol and patient factors in effectiveness in the improvement in exercise tolerance
73. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure. Effects on functional capacity, quality of life, and clinical outcomes
74. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
75. Pharmacotherapy for systolic dysfunction; a review of randomized clinical trials
76. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
77. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
78. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
79. Meta-analysis of observed mortality data from all-controlled, double blind, multiple-dose studies of losartan in heart failure
80. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil
81. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD pilot study)
82. Addition of angiotensin II receptor blockade to maximal angiotensive-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure
83. Wirksamkeit von digitalis bei patienten mit chronischer herzinsuffizienz und sinusrhythmus
84. The effect of digoxin on mortality and morbidity in patients with heart failure
85. Effect of oral milrinone on mortality in severe chronic heart failure
86. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial
87. Effect of metroprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure
88. Clinical effects of β-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trials
89. Which beta-blocker?
90. Effect of amiodipine on morbidity and mortality in severe chronic heart failure
91. The effects of spironolactone on morbidity and mortality in patients with severe heart failure
92. Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure
93. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials
94. A comparison of antiarrhythmic-drug therapy with implantable defibrillators 1 patients resuscitated from near-fatal ventricular arrhythmias
95. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
96. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery
97. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death
98. Prophylactic antiarrhythmic therapy for the prevention of sudden death in high-risk patients: Drugs and devices
99. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
100. Effects of captopril on ischaemic events after myocardial infarction
101. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
102. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function
103. Bone marrow cells regenerate infracted myocardium
104. Primary prevention
105. How well can we predict coronary heart disease? Findings of the United Kingdom heart disease prevention project
106. Sex differences in myocardial infarction and coronary deaths in the Scottish MONICA population of Glasgow 1985 to 1991: Presentation, diagnosis, treatment, and 28-day case fatality of 3991 events in men and 1551 events in women
107. Cardiovascular disease risk profiles
108. Physical activity and the incidence of coronary heart disease
109. A meta-analysis of physical activity in the prevention of coronary heart disease
110. Relation of physical activity and cardiovascular fitness to coronary heart disease. Part 1: A meta-analysis of the independent relation of physical activity and coronary heart disease
111. Effects of traditional coronary risk factors on rates of incident coronary events in a low-risk population: The Adventist health study
112. Self-report of physical activity and patterns of mortality in Seventh-Day Adventist men
113. Physical activity and incidence of coronary heart disease in middle-aged women and men
114. Risk factors for acute myocardial infarction in Copenhagen II: Smoking, alcohol intake, physical activity, obesity, oral contraception, diabetes, lipids and blood pressure
115. Risk due to inactivity in physically capable older adults
116. Association of leisure time physical activity with the risk of coronary heart disease, hypertension and diabetes in middle-aged men and women
117. Does exercise reduce mortality rates in the elderly? Experience from the Framingham heart study
118. Physical activity and 23-year incidence of coronary heart disease morbidity and mortality among middle-aged men: The Honolulu heart program
119. Self-reported physical activity predicts long-term coronary heart disease and all-cause mortalities: 21-year follow-up of the Israeli ischemic heart disease study
120. Physical activity at work and cardiovascular disease risk: Results from the MONICA Augsburg study
121. Leisure time physical activity and the 16-year risks of mortality from coronary heart disease and all-causes in the multiple risk factor intervention trial (MRFIT)
122. Impact of cardiovascular risk factors on morbidity and mortality in Czech middle-aged men: Pilsen longitudinal study
123. Impact of unhealthy behaviors on cardiovascular mortality in Finland, 1978-1993
124. Cardiovascular risk factors and 18-month mortality and morbidity in an elderly Chinese population aged 70 years and over
125. Prospective assessment of coronary heart disease risk factors: The Nhanes I epidemiologic follow-up study (NHEFS) 16-year follow-up
126. World and leisure time physical activity and mortality in men and women from a general population sample
127. Effects of walking on coronary heart disease in elderly men: The Honolulu heart program
128. Relation of physical activity and cardiovascular fitness to coronary heart disease, part II: Cardiovascular fitness and the safety and efficacy of physical activity prescription
129. Changes in physical fitness and all-cause mortality: A prospective study of healthy and unhealthy men
130. Leisure-time physical activity and ischemic stroke risk: The Northern Manhattan stroke study
131. Lifelong exposures and the potential for stroke prevention: The contribution of cigarette smoking, exercise, and body fat
132. Physical activity and stroke incidence in women and men. The NHANES I epidemiologic follow-up study
133. Physical activity and stroke risk: The Framingham study
134. Physical activity in older middle-aged men and reduced risk of stroke: The Honolulu heart program
135. Risk factors of stroke incidence and mortality: A 12-year follow-up of the Oslo study
136. Physical activity and stroke in British middle aged men
137. Twenty-year stroke mortality and prediction in twelve cohorts of the seven countries study
138. Risk factors for stroke in Copenhagen, Denmark. II. Lifestyle factors
139. Lifestyle factors and risk of cerebrovascular disease in women: The Copenhagen city heart study
140. Evidence of hypertension and stroke in relation to body fat distribution and other risk factors in older women
141. A 15.5 year follow-up study of stroke in a Japanese provincial city; the Shibata study
142. Exercise and risk of stroke in male physicians
143. Physical activity and ischemic stroke risk: The atherosclerosis in communities study
144. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion: Determinants of myocardial infarction onset study investigators
145. Physical exertion as a trigger of acute myocardial infarction: Triggers and mechanisms of myocardial infarction study group
146. Physical activity and public health. A recommendation from the center for disease control and prevention and the American college of sports medicine
147. The cardiovascular complications of vigorous physical activity
148. Exercise and the primary prevention of cardiovascular disease
149. Effects of lifestyle activity vs. structured aerobic exercise in obese women: A randomized trial
150. Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: A randomized trial
151. A randomized walking trial in postmenopausal women: Effects on physical activity and health 10 years later
152. Training effects of long versus short bouts of exercise in healthy subjects
153. Changes in physical fitness and changes in mortality
154. Exercise in the menopausal woman
155. A randomized controlled trial to evaluate the efficacy of community based physical therapy in the treatment of people with rheumatoid arthritis
156. A randomized controlled trial of weight reduction and exercise for diabetes management in older African-American subjects
157. Increased interleukin-1b in human skeletal muscle after exercise
158. Effects of anaerobic exercise on the immune system in eight to seventeen year old trained and untrained boys
159. Immune response to heavy exertion
160. A prospective study of respiratory infections in 12 year old children actively engaged in sports
161. Exercise dysfunction in patients seropositive for the human immunodeficiency virus
162. Supervised exercise training improves cardiopulmonary fitness in HIV-infected persons
163. Association between exercise and HIV disease progression in a cohort of homosexual men
164. Progressive resistance exercise: Effect on muscle function and anthropometry of a select AIDS population
165. Feasibility of increasing lean body mass in HIV-infected adults using progressive resistance exercise
166. Effects of exercise training on men seropositive for the human immunodeficiency virus-1
167. Aerobic exercise training in an AIDS risk group
168. Aerobic circuit training: Effect on adolescents with well-controlled insulin-dependent diabetes mellitus
169. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution
170. Fruit and vegetables and cardiovascular disease: A review
171. By how much does fruit and vegetable consumption reduce the risk of ischaemic heart disease?
172. Dietary habits and mortality in 11,000 vegetarians and health conscious people: Results of a 17 year follow up
173. Intake of dietary fibre and risk of coronary heart disease in a cohort of Finnish men
174. Dietary determinants of ischaemic heart disease in health conscious individuals
175. Dietary antioxidant vitamins and fiber in the etiology of cardiovascular disease and all-cause mortality: Results from the Scottish heart health study
176. Fruit and vegetable intake reduces cardiovascular mortality; results from the NHANES I epidemiologic follow-up study (NHEFS)
177. Fruit and vegetable intake and risk of cardiovascular disease
178. Vegetable consumption and risk of coronary heart disease in men: Results from the physicians health study
179. Antioxidant vitamin intake and coronary mortality in a longitudinal population study
180. Dietary flavonoids, antioxidant vitamins, and incidence of stroke
181. Dietary vitamin C, beta-carotene and 30 year risk of stroke: Results from the Western electric study
182. Prospective study of potassium intake and risk of stroke among US men
183. Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women
184. Quercetin intake and the incidence of cerebrovascular disease
185. Fruit and vegetable intake in relation to risk of ischemic stroke
186. Does eating fruit and vegetables protect against heart attack and stroke?
187. Dietary habits and mortality in vegetables and health conscious people: Several uncertainities exist
188. The association between fruit and vegetable intake and chronic disease risk factors
189. Is there a role for antioxidant vitamins in the prevention of cardiovascular disease? An update on epidemiological and clinical trials data
190. The antioxidant vitamins and cardiovascular disease: A critical review of epidemiologic and clinical trial data
191. Antioxidants and coronary heart disease: Observational studies
192. Spurious precision? Meta-analysis of observational studies
193. Randomized trials of dietary antioxidants in cardiovascular disease prevention and treatment
194. Vitamin C and cardiovascular disease - A systemic review
195. Dietary antioxidants and risk of myocardial infarction in the elderly: The Rotterdam study
196. Relation of consumption of vitamin E, vitamin C and carotenoids to risk for stroke among men in the United States
197. Nutrition intervention trials in Linxian, China: Multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia
198. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation
199. Do nutritional supplements lower the risk of stroke or hypertension?
200. Vitamin E and vitamin C supplement use and risk of all-cause and coronary mortality in older persons: The established populations for epidemiologic studies of the elderly
201. Carotenoids, vitamin C and E and mortality in an elderly population
202. Dietary flavonoids, antioxidant vitamins, and incidence of stroke
203. Selenium as a risk factor for cardiovascular disease
204. Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen elderly study
205. Flavonoid intake and coronary mortality in Finland: A cohort study
206. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals
207. Antioxidant flavonoids and ischemic heart disease in a Welsh population of men: The caerphilly study
208. Antioxidant vitamins, cancer, and cardiovascular disease
209. Antioxidant vitamins, cancer and cardiovascular disease
210. Antioxidant vitamin cardiovascular disease hypothesis is still promising, but still unproven; the need for randomised trials
211. Biochemical markers for nutrient intake
212. The effect of vitamin E and beta carotene on the incidence of lung cancer and other causes in male smokers
213. Mortality in relation to smoking: 40 years' observations on male British doctors
214. Smoking cessation in relation to total mortality rates in women: A prospective cohort study
215. The risk of myocardial infarction after quitting smoking in men under 55 years of age
216. Decline in the risk of myocardial infarction among women who stop smoking
217. A randomised controlled trial of anti-smoking advice: 10-year results
218. Meta-analysis of relation between cigarette smoking and stroke
219. Smoking and causes of death among US veterans: 16 years of observation
220. History of parental death from stroke or heart trouble and the risk of stroke in middle-aged men
221. Drugs for hypertension
222. The effectiveness of exercise training in lowering blood pressure; a meta-analysis of randomised controlled trials of 4 weeks or longer
223. Lowering blood pressure: A systematic review of sustained non-pharmacological interventions
224. Hypertensive men who exercise regularly have lower rate of cardiovascular mortality
225. A clinical trial of the effects of dietary patterns on blood pressure
226. Alcohol and hypertension: Kill or cure?
227. Recommendations on alcohol consumption
228. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride
229. Sodium reduction and weight loss in the treatment of hypertension in older persons: A randomized controlled trial of non pharmacologic interventions in the elderly (TONE)
230. Effect of reduced dietary sodium on blood pressure
231. Low urinary sodium associated with greater risk of myocardial infarction among treated hypertensive men
232. Weight-reducing diets for control of hypertension in adults
233. Effects of oral potassium on blood pressure: Meta-analysis of randomized controlled clinical trials
234. Does fish oil lower blood pressure? A meta-analysis of controlled clinical trials
235. The influence of dietary and nondietary calcium supplementation on blood pressure
236. New meta-analysis of treatment trials of hypertension: Improving the estimate of therapeutic benefit
237. Risks of untreated and treated isolated systolic hypertension in the elderly: Meta-analysis of outcome trials
238. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
239. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
240. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) trial
241. Does diuretic therapy increase the risk of renal cell carcinoma?
242. Quality of life in treatment of hypertension: A meta-analysis of clinical trials
243. The effects of antihypertensive therapy on quality of life
244. Health outcomes associated with antihypertensive therapies used as first line agents: A systematic review and meta-analysis
245. Are beta blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review
246. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The captopril prevention project (CAPP) randomised trial
247. Randomized trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study
248. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
249. Treatment of mild hypertension study: Final results
250. Single drug therapy for hypertension in men
251. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: Results of the HANE study
252. Systematic review of antihypertensive therapies: Does the evidence assist in choosing a first line drug?
253. Calcium channel blockers for hypertension - Uncertainty continues
254. Collaborative overview of randomised trials of antiplatelet therapy - 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
255. Aspirin for the primary prevention of stroke and other major vascular events. Meta-analysis and hypotheses
256. Thrombosis prevention trial: Randomised trial of low-intensity anticoagulation with warfarin and low dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
257. Randomised trial of prophylactic daily aspirin in British male doctors
258. Final report on the aspirin component of the ongoing physicians' health study
259. Women's health study: Summary of the study design
260. Variability in meta-analytic results concerning the value of cholesterol reduction in coronary heart disease: A meta-meta-analysis
261. Measurement and management of hyperlipidemia for the primary prevention of coronary heart disease
262. What role for statins? A review and economic model
263. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
264. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of the AFCAPS/TexCAPS
265. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S)
266. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
267. Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
268. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
269. Cholesterol reduction yields clinical benefit: Impact on statin trials
270. Systematic review on the risk and benefit of different cholesterol-lowering interventions
271. Managing dyslipidaemia in older adults
272. Colesevelam (Welchol) for hypercholesterolemia
273. Statins as a newly recognized type of immunomodulator
274. Immunomodulation: A new role for statins?
275. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study
276. Drugs for HIV infection
277. Interactions among drugs for HIV and opportunistic infections
278. Cardiovascular abnormalities in HIV-infected individuals
279. AIDS and the cardiovascular system
280. Cardiac disease